title: Summary of the British Transplantation Society Guidelines for the Prevention and Management of CMV Disease After Solid Organ Transplantation.
abstract: The third edition of the British Transplantation Society Guidelines for the Prevention and Management of CMV Disease after Solid Organ Transplantation was published in March 2011. This article summarizes the important changes and advances in management in this rapidly evolving field. The pros and cons of universal, or targeted anti-cytomegalovirus (CMV) prophylaxis, and pre-emptive anti-CMV therapy are discussed, especially with respect to advances in CMV polymerase chain reaction monitoring. The evidence for oral anti-CMV prophylaxis using valganciclovir is presented, together with a summary of the treatment of CMV disease and emerging fields such as CMV vaccination, CMV genotyping, and drug resistance.
authors: SW Thames Renal & Transplantation Unit, St. Helier Hospital, Surrey, UK. peter.andrews@esth.nhs.uk
authors: Peter A
authors: PA
authors: Andrews
authors: Vincent C
authors: VC
authors: Emery
authors: Chas
authors: C
authors: Newstead
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000517:prevention & control*; D024882:Drug Resistance, Viral; D015774:Ganciclovir / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D016377:Organ Transplantation / Q000009:adverse effects*; D017410:Practice Guidelines as Topic; D006113:United Kingdom; D000077562:Valganciclovir
chemical_list: D000998:Antiviral Agents; D000077562:Valganciclovir; D015774:Ganciclovir